ELSEVIER

Contents lists available at ScienceDirect

Biophysical Chemistry

journal homepage: http://www.elsevier.com/locate/biophyschem



Comment on: Construction of simplified models to simulate estrogenic disruptions by esters of 4-hydroxybenzoic acid (parabens). Patricia Guadarrama, Serguei Fomine, Roberto Salcedo, Ana Martínez. Biophys. Chem. 137 (2008) 1–6. doi:10.1016/j.bpc2008.06.001

Dene Godfrey*

S. Black Ltd., Foxholes Business Park, Hertford, Herts SG13 7YH, UK

ARTICLE INFO

Article history:
Received 11 August 2008
Received in revised form 26 August 2008
Accepted 10 September 2008
Available online 16 September 2008

I wish to point out several serious failings in the conclusions of this recent paper [1]. Both claims – that methylparaben is the most potent oestrogen mimic and the most active antibacterial compound amongst the parabens - are in direct contravention with all the published evidence to date. Several groups have studied the oestrogenic activities of some of the parabens using the rat uterotrophic assay, including Routledge [2] and Houssani [3] and, in all cases methylparaben was concluded to be orders of magnitude weaker than butylparaben. For example, Routledge determined that methylparaben was 2,500,000 times weaker than oestradiol, whereas butylparaben was only 10,000 times weaker than oestradiol in their in vitro study. It may be concluded, therefore, that methylparaben is 250 times weaker than butylparaben. Indeed, in Routledge's in vivo study [2], methylparaben demonstrated no detectable oestrogenic activity, compared with butylparaben being determined as 100,000 times weaker than oestradiol. From these data it is difficult to accept that the model proposed by the authors of [1] has any semblance of accuracy.

The authors' claim that the results obtained are in agreement with experimental studies of extraction and quantification of parabens in tumours is totally illogical, since the study to which the authors refer, by Darbre et al. [4] contains no determination of oestrogenic activity, and only claims to have detected the presence of parabens in the tumours. There is no connection between the presence of parabens and their relative potency as oestrogen mimics as neither the presence, nor the relative concentrations present can be indicative of relative oestrogenic activity. It is difficult, therefore, to comprehend how the authors concluded that methylparaben is more oestrogenic

The claim that methylparaben is the most potent antibacterial amongst the parabens is not borne out by the wealth of data available from any manufacturer or supplier of these materials. Table 1 lists the minimum inhibitory concentrations of methylparaben against a range of bacteria and, for comparison, against some fungi.

The data in Table 1 are typical of the values quoted by all parabens manufacturers.

Table 1Minimum inhibitory concentrations (mic) of parabens against various microbial species [5]

Organism	Paraben	mic (%)
Pseudomonas aeruginosa (bacterium)	Methylparaben	0.200
Pseudomonas aeruginosa	Ethylparaben	0.120
Pseudomonas aeruginosa	Propylparaben	0.080
Pseudomonas aeruginosa	Butylparaben	0.015
Staphylococcus aureus (bacterium)	Methylparaben	0.160
Staphylococcus aureus	Ethylparaben	0.120
Staphylococcus aureus	Propylparaben	0.045
Staphylococcus aureus	Butylparaben	0.015
Candida albicans (fungus)	Methylparaben	0.100
Candida albicans	Ethylparaben	0.060
Candida albicans	Propylparaben	0.025
Candida albicans	Butylparaben	0.015
Aspergillus niger (fungus)	Methylparaben	0.085
Aspergillus niger	Ethylparaben	0.045
Aspergillus niger	Propylparaben	0.035
Aspergillus niger	Butylparaben	0.025

than butylparaben simply because it appeared to be present in the tissues tested at a higher concentration. Indeed, the Darbre study fails to prove conclusively the presence of parabens in tumour tissue as the blank samples were also found to contain parabens, and at concentrations statistically indistinguishable from those found in the tumours themselves.

DOI of original article: 10.1016/j.bpc.2008.09.008.

^{*} Tel.: +44 1992 825555; fax: +44 1992 825566. E-mail address: dgodfrey@sblack.com.

The lower the minimum inhibitory concentration, the more powerful the activity and it is very clear that the order of activity is methylparaben<ethylparaben<pre>propylparaben
butylparaben for all organisms. This is entirely the opposite of what is claimed by the authors for their model and, therefore, it must surely be concluded that this model is not suitable for purpose.

Declaration of interest: The author is employed by S. Black Ltd., a distributor of raw materials to the personal care industry. The company supplies parabens and most other preservatives commonly used in this industry.

References

- [1] P. Guadarrama, S. Fomine, R. Salcedo, A. Martínez, Construction of simplified models to simulate estrogenic disruptions by esters of 4-hydroxy benzoic acid (parabens), Biophys. Chemist. 137 (2008) 1–6.
- [2] E.J. Routledge, J. Parker, J. Odum, J. Ashby, J.P. Sumpter, Some alkyl hydroxybenzoate preservatives (parabens) are oestrogenic, Toxicol. Appl. Pharmacol. 153 (1998) 12–19.
- [3] A. Hossaini, J-J. Larsen, J.C. Larsen, Lack of oestrogenic effects of food preservatives (parabens) in uterotrophic assays, Food Chem. Toxicol. 38 (2000) 319–323.
- [4] P.D. Darbré, A. Aljarrah, W.R. Miller, N.G. Coldham, M.J. Sauer, G.S. Pope, Concentrations of parabens in human breast tumours, J. Appl. Toxicol. 24 (2004) 5–13.
- [5] S. Black Ltd. Paratexin product literature www.sblack.com.